PR Newswire

nference and Novo partner to advance understanding of cardiometabolic disease and healthy ageing

The story

The collaboration brings together Novo’s clinical trial research and nference’s AI and federated healthcare data network to study cardiometabolic disease, treatment outcomes, and healthy ageing.

Announced on November 18, 2026, the partnership focuses on obesity, diabetes, cardiovascular disease, and the broader patient journey. Researchers will connect clinical studies with information from routine care to explore treatment effectiveness, safety, disease progression, and long-term health.

The research agenda includes clinical pharmacology, combination therapies, and precision trials that consider whole-body health alongside weight loss. A parallel framework will explore new AI-focused ventures addressing needs in cardiometabolic health and healthy ageing.

View original source

Your next question could change everything.

What will you
discover next?

Let’s find out
Ideas are connected. Your next discovery starts here.